Literature DB >> 23652082

Japan to offer fast-track approval path for stem cell therapies.

David Cyranoski.   

Abstract

Mesh:

Year:  2013        PMID: 23652082     DOI: 10.1038/nm0513-510

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  7 in total

1.  The global intellectual property landscape of induced pluripotent stem cell technologies.

Authors:  MacKenna Roberts; Ivan B Wall; Ian Bingham; Dominic Icely; Brock Reeve; Kim Bure; Anna French; David A Brindley
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

Review 2.  Cellular Therapies in Trauma and Critical Care Medicine: Forging New Frontiers.

Authors:  Shibani Pati; Marcello Pilia; Juanita M Grimsley; Alexia T Karanikas; Blessing Oyeniyi; John B Holcomb; Andrew P Cap; Todd E Rasmussen
Journal:  Shock       Date:  2015-12       Impact factor: 3.454

3.  The pluralization of the international: Resistance and alter-standardization in regenerative stem cell medicine.

Authors:  Achim Rosemann; Nattaka Chaisinthop
Journal:  Soc Stud Sci       Date:  2016-02       Impact factor: 3.885

Review 4.  The clinical potential of gene editing as a tool to engineer cell-based therapeutics.

Authors:  Candice Ashmore-Harris; Gilbert O Fruhwirth
Journal:  Clin Transl Med       Date:  2020-02-07

5.  Clinical translation of stem cell therapy for spinal cord injury still premature: results from a single-arm meta-analysis based on 62 clinical trials.

Authors:  Zhizhong Shang; Mingchuan Wang; Baolin Zhang; Xin Wang; Pingping Wanyan
Journal:  BMC Med       Date:  2022-09-05       Impact factor: 11.150

Review 6.  Managing the potential and pitfalls during clinical translation of emerging stem cell therapies.

Authors:  Heather Main; Megan Munsie; Michael D O'Connor
Journal:  Clin Transl Med       Date:  2014-05-09

7.  Why clinical translation cannot succeed without failure.

Authors:  Alex John London; Jonathan Kimmelman
Journal:  Elife       Date:  2015-11-24       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.